Abstract

Currently, the pulmonary route has obtained a lot of research attention as a parallel non-invasive way for drug delivery to both local tissue and systemic circulation. Different devices for delivering the bioactive through pulmonary routes are available in the market, but none of them possess the required qualities for efficient and optimal pulmonary delivery. Recently the massive development in the area of pharmaceutical nanotechnology has opened the door of opportunity for fabrication and clinical implementation of inhalable nanomedicines with the ability to target specific sustained and controlled pulmonary delivery of drugs. Several studies suggest the ability of liposomes and solid lipid nanoparticles (SLNs) as lucrative nanocarriers for delivering the drugs through the pulmonary route. But still, we have a fragmented understanding regarding how the drug carriers and the individual parts of the carriers (as opposed to the loaded drugs) are disposed of from the lungs. In this way, it becomes significant to clarify the kinetics of the carriers in the lungs after pulmonary administration. This chapter possesses an aim to give a clear understanding regarding the mechanism and pharmacokinetic attributes of the clearance of liposomes and SLNs from lungs after administering through pulmonary route.